A Phase I/II Dose Escalation Study of TKM-080301, a RNAi Therapeutic Directed Against PLK1, in Patients with Advanced Solid Tumors, with an Expansion Cohort of Patients with NET or ACC
Journal article published in 2014 by
Ramesh K. Ramanathan,
Solomon I. Hamburg,
Thorvardur R. Halfdanarson 
,
Mitesh J. Borad,
Mahesh Seetharam,
Kelly K. Curtis,
Peter Lee,
Paul Fredlund,
Mark Gilbert,
Sean C. Semple,
Adam D.,
Brynne Crowell,
Linda Vocila,
Ian MacLachlan,
Donald W. Northfelt
,
Mitesh J. Borad,
Mahesh Seetharam,
Kelly K. Curtis,
Peter Lee,
Paul Fredlund,
Mark Gilbert,
Sean C. Semple,
Adam D.,
Brynne Crowell,
Linda Vocila,
Ian MacLachlan,
Donald W. Northfelt
